ELOXX PHARMACEUTICALS, INC. (ELOX) Operating income 2016–2025
ELOXX PHARMACEUTICALS, INC. (ELOX) annual operating income history from SEC filings — each fiscal year as reported.
-$6.4MFY2025 · since FY2016: -$2.2M → -$6.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$6.4M | -160.9% |
| FY2024 | -$2.5M | +85.7% |
| FY2023 | -$17.3M | +49.8% |
| FY2022 | -$34.4M | +47.9% |
| FY2021 | -$66.0M | -97.3% |
| FY2020 | -$33.5M | +33.8% |
| FY2019 | -$50.6M | -6.3% |
| FY2018 | -$47.6M | -133.3% |
| FY2017 | -$20.4M | -822.4% |
| FY2016 | -$2.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ELOX financial trends
ELOX RevenueELOX Net incomeELOX Net marginELOX Gross profitELOX Gross marginELOX Operating marginELOX Operating cash flowELOX Free cash flowELOX Capital expendituresELOX Return on equityELOX Stock buybacksELOX Dividends paidELOX Total assetsELOX Total liabilitiesELOX Shareholders’ equityELOX overview →